ProSense® Kidney Cryoablation
Renal cell carcinoma ≤5 cm
CE‑marked, FDA‑cleared (commercial)Active
Key Facts
Indication
Renal cell carcinoma ≤5 cm
Phase
CE‑marked, FDA‑cleared (commercial)
Status
Active
Company
About IceCure Medical
IceCure provides a liquid‑nitrogen cryoablation platform for minimally invasive tumor destruction across multiple oncology indications.
View full company profile